MET and prostate carcinoma: In prostate cancer, tyrosine kinase inhibitors targeting signaling pathways of EGFR, VEGFR, c-SRC family kinases, platelet-derived growth factor and c-MET showed encouraging results in pre-clinical settings but these finding are still waiting to be realized as anticancer drugs as phase III clinical trials did not produce satisfying results [421].